Back to search
FDAFDA · Food and drugs·Recall number D-0731-2022

TESTOSTERONE CYPIONATE/ ANASTROZOLE *GS* OIL (10ML) 200MG/0.5MG/ML; Packaged in a multi dose 10ML vial, as a) (CA) 4 ML Formula ID 136164; b) (RM) 10 ML Formula ID 115962; APS Phar

Published April 6, 2022 · Recall initiated: March 23, 2022

Summary

FDA records drug Class II recall D-0731-2022, published April 6, 2022 and initiated March 23, 2022. Recalling firm: Drug Depot, Inc., dba APS Pharmacy; Status: Terminated; Reported quantity: 73 vials; Lot: Lots: a)750851 BUD: 7/18/2022; b) 754549 BUD: 8/2/2022. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Lack of sterility assurance.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Drug Depot, Inc., dba APS Pharmacy
Distributor
Nationwide in the USA including Puerto Rico.
Lot
Lots: a)750851 BUD: 7/18/2022; b) 754549 BUD: 8/2/2022
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was TESTOSTERONE CYPIONATE/ ANASTROZOLE *GS* OIL (10ML) 200MG/0.5MG/ML; Packaged in a multi dose 10ML vial, as a) (CA) 4 ML Formula ID 136164; b) (RM) 10 ML Formula ID 115962; APS Phar recalled?

Yes. FDA published recall D-0731-2022 on April 6, 2022. Reported hazard: Lack of sterility assurance.

What should I do if I have this product?

Voluntary: Firm initiated · Letter